AOD-9604: an old GH-fragment idea

Plain-language summary

AOD-9604 is a fragment of human growth hormone (the 176–191 region) that was investigated for fat metabolism without the full anabolic profile of intact GH. Some early human and preclinical work explored fat-loss endpoints, but the results have been mixed and modest—nowhere near the consistency or effect size of today's incretin therapies.

What was studied

Early human and preclinical studies of AOD-9604's effects on carbohydrate and lipid metabolism, examining whether the fragment could drive lipolysis-related endpoints.

Key takeaways

• The concept was a GH-derived fragment aimed at fat metabolism without broad GH agonism.
• Early human exploration exists, so it's tagged “limited human”—but the base is older and mixed.
• Effect sizes did not hold up against modern obesity therapeutics in later comparisons.
• Historically interesting more than practically compelling today.

Limitations & what we don't know

• The evidence base is older, smaller, and inconsistent.
• Not a substitute for lifestyle changes or approved obesity therapies.
• Gray-market product authenticity is a recurring diligence issue.
• No modern large RCTs establishing meaningful fat loss.

1. 1.

   The effects of the human GH fragment AOD9604 on carbohydrate and lipid metabolism

   2000 · human

   Early human metabolic exploration.